Maxim Group analyst Jason McCarthy has maintained their bullish stance on GNLX stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jason McCarthy has given his Buy rating due to a combination of factors including the promising progress of Genelux Corp.’s lead asset, Olvi-Vec, which is currently undergoing a pivotal Phase 3 trial for ovarian cancer. The trial is evaluating the efficacy of Olvi-Vec in combination with chemotherapy and Avastin, with top-line data expected in the first half of 2026, marking a significant potential catalyst for the company’s stock.
Additionally, the company’s ongoing lung cancer programs, which are partner-funded, show promise with upcoming data readouts expected for both non-small cell lung cancer and small cell lung cancer. The innovative mechanism of Olvi-Vec, which includes direct cancer cell lysis and immune system activation, further supports its potential efficacy. The financial outlook, with sufficient cash reserves projected to last into the second half of 2026, also contributes to the positive rating. The valuation model anticipates commercialization in the U.S. by 2027 for ovarian cancer and by 2029 for lung cancer, with a calculated 12-month price target of $10.
In another report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $31.00 price target.
Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of GNLX in relation to earlier this year.